Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Non-Current Deffered Revenue (2022 - 2025)

Stoke Therapeutics has reported Non-Current Deffered Revenue over the past 4 years, most recently at $7.0 million for Q4 2025.

  • Quarterly results put Non-Current Deffered Revenue at $7.0 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $7.0 million (changed N/A YoY), and the annual figure for FY2025 was $7.0 million, changed.
  • Non-Current Deffered Revenue for Q4 2025 was $7.0 million at Stoke Therapeutics, down from $8.6 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for STOK hit a ceiling of $49.5 million in Q1 2022 and a floor of $7.0 million in Q4 2025.
  • Median Non-Current Deffered Revenue over the past 4 years was $33.1 million (2023), compared with a mean of $27.3 million.
  • Biggest five-year swings in Non-Current Deffered Revenue: tumbled 79.64% in 2024 and later increased 3.22% in 2025.
  • Stoke Therapeutics' Non-Current Deffered Revenue stood at $36.9 million in 2022, then dropped by 10.26% to $33.1 million in 2023, then plummeted by 74.93% to $8.3 million in 2024, then dropped by 16.04% to $7.0 million in 2025.
  • The last three reported values for Non-Current Deffered Revenue were $7.0 million (Q4 2025), $8.6 million (Q3 2025), and $9.6 million (Q2 2025) per Business Quant data.